Philippe Close

2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014

College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban.

Parenteral Anticoagulants

Parenteral Anticoagulants

Anticoagulant Use in Patients with Chronic Renal Impairment

A Meta-Analysis of Thromboembolic Prophylaxis Following Elective Total Hip Arthroplasty*

Regional anesthesia in the anticoagulated patient: Defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation)

Simultaneous comparison of multiple treatments: combining direct and indirect evidence

Heparininduzierte Thrombozytopenie als Komplikation der postoperativen Thromboseprophylaxe mit UFH/NMH-Heparinen nach Hüft- und Knieendoprothetik

A Comparison of Hirudin with Heparin in the Prevention of Restenosis after Coronary Angioplasty

Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery

Heparin-Induced Thrombocytopenia

A Clinical Trial of Vena Caval Filters in the Prevention of Pulmonary Embolism in Patients with Proximal Deep-Vein Thrombosis

Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

Relationships Between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry

Design and Synthesis of Potent and Highly Selective Thrombin Inhibitors

Controversies in Timing of the First Dose of Anticoagulant Prophylaxis Against Venous Thromboembolism After Major Orthopedic Surgery

Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery

Prevention of venous thromboembolism

A Fast Flexible Docking Method using an Incremental Construction Algorithm

Heparin-Induced Thrombocytopenia: Recognition, Treatment, and Prevention

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

Fondaparinux vs Enoxaparin for the Prevention of Venous Thromboembolism in Major Orthopedic Surgery<subtitle>A Meta-analysis of 4 Randomized Double-blind Studies</subtitle>

Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial

Antithrombotic Therapy for VTE Disease

Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study

Effect of pegylation on pharmaceuticals

Antithrombotic Therapy for Venous Thromboembolic Disease

Risk of Anaphylaxis After Reexposure to Intravenous Lepirudin in Patients With Current or Past Heparin-Induced Thrombocytopenia

Treatment and Prevention of Heparin-Induced Thrombocytopenia

2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin/Out-of-Hospital Placebo in Hip Arthroplasty Patients

Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients

Duration of Venous Thromboembolism Prophylaxis After Surgery

Thromboprophylaxis with 60 mg Enoxaparin Is Safe in Hip Trauma Surgery

Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease

Dose-escalation study of rivaroxaban (BAY 59-7939) – an oral, direct Factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement

Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study

Bivalent direct thrombin inhibitors: hirudin and bivalirudin

The Pharmacokinetics and Pharmacodynamics of Argatroban: Effects of Age, Gender, and Hepatic or Renal Dysfunction

BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

Elevated serum creatinine is associated with 1-year mortality after acute myocardial infarction

Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism

Antithrombotic Therapy for VTE Disease

Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery

The Assessment of Deep Vein Thromboses for Therapeutic Trials

Anatomy of hot spots in protein interfaces

Crystallographic determination of the structures of human α‐thrombin complexed with BMS‐186282 and BMS‐189090

A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement

Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology

Heparin-Induced Thrombocytopenia

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Preoperative or Postoperative Start of Prophylaxis for Venous Thromboembolism With Low-Molecular-Weight Heparin in Elective Hip Surgery?

Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial

Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin in Close Proximity to Surgery vs Warfarin in Hip Arthroplasty Patients

PROPHYLAXIS OF DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM

Prevention of Venous Thromboembolism

Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer

Pre-eclampsia

Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement

Neuraxial Anesthesia and Low-Molecular-Weight Heparin Prophylaxis in Major Orthopedic Surgery in the Wake of the Latest American Society of Regional Anesthesia Guidelines

A New Therapeutic Option by Subcutaneous Recombinant Hirudin in Patients with Heparin-induced Thrombocytopenia Type II

Recombinant hirudin (HBW 023) prevents troponin T release after coronary angioplasty in patients with unstable angina

Development of a Novel Recombinant Serpin with Potential Antithrombotic Properties

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement

Superiority of Fondaparinux Over Enoxaparin in Preventing Venous Thromboembolism in Major Orthopedic Surgery Using Different Efficacy End Points

Short-Duration Prophylaxis Against Venous Thromboembolism After Total Hip or Knee Replacement

Prevention of Venous Thromboembolism

Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study

Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study

Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy

Reporting of Noninferiority and Equivalence Randomized Trials

A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease

Antithrombotic Therapy for Venous Thromboembolic Disease

Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison

Preoperative vs Postoperative Initiation of Low-Molecular-Weight Heparin Prophylaxis Against Venous Thromboembolism in Patients Undergoing Elective Hip Replacement

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement

Protein therapeutics: a summary and pharmacological classification

Bilateral vs. ipsilateral venography as the primary efficacy outcome measure in thromboprophylaxis clinical trials: a systematic review

Prevention of Venous Thromboembolism

Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag

New antithrombotic agents

New Antithrombotic Agents

Extended Out-of-Hospital Low-Molecular-Weight Heparin Prophylaxis against Deep Venous Thrombosis in Patients after Elective Hip Arthroplasty

Guidelines for the Early Management of Patients With Acute Ischemic Stroke

Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy

Kidney Disease as a Risk Factor for Development of Cardiovascular Disease

Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes

Molecular Recognition of Protein−Ligand Complexes:  Applications to Drug Design

The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Serpin Structure, Mechanism, and Function

Optimization of ascending phlebography of the leg for screening of deep vein thrombosis in thromboprophylactic trials

Factor V Leiden (G1691A) and Prothrombin Gene G20210A Mutations as Potential Risk Factors for Venous Thromboembolism after Total Hip or Total Knee Replacement Surgery

A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip Replacement

Natural History of Venous Thromboembolism

Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

Potent Antithrombin Activity and Delayed Clearance From the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin

Preparation of Porous Polysaccharides Templated by Coordination Polymer with Three-Dimensional Nanochannels

Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension

ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY

Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance

Anaphylactic and Anaphylactoid Reactions Associated With Lepirudin in Patients With Heparin-Induced Thrombocytopenia

Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.

Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review.

Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance

Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty

2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Generation of Anti-Hirudin Antibodies in Heparin-Induced Thrombocytopenic Patients Treated With R-Hirudin

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Low Molecular Weight Heparin Decreases Proximal and Distal Deep Venous Thrombosis Following Total Knee Arthroplasty

Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin.

Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery

Low-Molecular-Weight Heparins

Development and validation of a predictive model for chemotherapy-associated thrombosis

Diagnostic Accuracy of Compression Ultrasonography for the Detection of Asymptomatic Deep Venous Thrombosis in Medical Patients

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Prevention of deep-vein thrombosis after total hip and knee replacement

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

Fluorescence-Based Blood Coagulation Assay Device for Measuring Activated Partial Thromboplastin Time

Prevention of Deep Vein Thrombosis after Hip Replacement

Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia

Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: A 1-year experience in 57 patients

Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty

ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina11This document was approved by the American College of Cardiology Board of Trustees in March 1999, the American Heart Association Science Advisory and Coordinating Committee in March 1999, and the American College of Physicians-American Society of Internal Medicine Board of Regents in February 1999.When citing this document, please use the following citation format: Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, Grunwald MA, Levy D, Lytle BW, O’Rourke RA, Schafer WP, Williams SV. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999;33:2092–197.This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org) and the American Heart Association (www.americanheart.org). Reprints of this document are available by calling 1-800-253-4636 or writing the American College of Cardiology, Educational Services, at 9111 Old Georgetown Road, Bethesda, MD 20814-1699. Ask for reprint number 71-0166. To obtain a reprint of the Executive Summary and Recommendations published in the June 1, 1999 issue of Circulation, ask for reprint number 71-0167. To purchase bulk reprints (specify version and reprint number): Up to 999 copies call 1-800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies call 214-706-1466, fax 214-691-6342, or e-mail pubauth@heart.org

Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis

Regional Anesthesia in the Anticoagulated Patient

Recombinant Hirudin in Clinical Practice

Weak allergenicity of recombinant hirudin CGP 39393 (REVASC) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group).

Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin

Prevention of Thromboembolism with Use of Recombinant Hirudin. Results of a Double-Blind, Multicenter Trial Comparing the Efficacy of Desirudin (Revasc) with That of Unfractionated Heparin in Patients Having a Total Hip Replacement*

Clinical Pharmacology of Intravenously Administered Recombinant Desulfatohirudin (CGP 39393) in Healthy Volunteers

A Comparison of Recombinant Hirudin with a Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement

Biologic effects of recombinant hirudin (CGP 39393) in human volunteers

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393

Effect of a 15-Minute Infusion of DDAVP on the Pharmacokinetics and Pharmacodynamics of ™REVASC during a Four-Hour Intravenous Infusion in Healthy Male Volunteers

Percentage of Inadequate Phlebograms and Observer Agreement in Thromboprophylactic Multicenter Trials Using Standardized Methodology and Central Assessment

Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.

Direct Thrombin Inhibition with Rec-Hirudin CGP 39393 as Prophylaxis of Thromboembolie Complications after Total Hip Replacement

Open Study of Intravenous Recombinant Hirudin (CGP 39393) on Platelet Function and Coagulation in Healthy Volunteers